FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2057928770> ?p ?o ?g. }

• W2057928770 endingPage "477" @default.
• W2057928770 startingPage "471" @default.
• W2057928770 abstract "To evaluate the efficacy, tolerability and safety of darifenacin, an M3 selective receptor antagonist, in the subgroup of older patients from a pooled analysis of three phase III, multicentre, randomized, double-blind clinical trials in patients with overactive bladder (OAB). 317 patients aged ≥65 years with OAB symptoms (urge incontinence, urgency and frequency) received up to 12 weeks’ oral treatment with darifenacin 7.5 mg or 15 mg once daily or matching placebo. Efficacy was evaluated from daily electronic diary records. Safety endpoints included withdrawal rates and treatment-related adverse events. Darifenacin treatment of patients aged ≥65 years was associated with a dose-related, significant improvement of all the major symptoms of OAB. At week 12, the median reduction in incontinence episodes/week was greater with darifenacin 7.5 mg or 15 mg than in the corresponding placebo arms (66.7% vs. 34.8% and 75.9% vs. 44.8%, respectively, both p < 0.001). Both doses were also significantly superior to placebo in improving micturition frequency (both p < 0.001), bladder capacity (volume voided) (darifenacin 7.5 mg, p = 0.018, darifenacin 15 mg, p < 0.001), and the frequency of urgency episodes (both p < 0.001). Darifenacin was well tolerated. The most common treatment-related adverse events were dry mouth (7.5 mg, 20.6%; 15 mg, 30.9%; placebo, 4.5%) and constipation (7.5 mg, 18.6%; 15 mg, 23.6%; placebo, 6.4%), typically mild or moderate. Use of constipation remedies (laxatives, stool softeners or fibre supplements) was low and similar between groups (7.5 mg, 10.3%; 15 mg, 16.4%; placebo, 10.0%). There were few withdrawals due to treatment-related adverse events (7.5 mg, 1.0%; 15 mg, 9.1%; placebo, 2.7%), and no nervous system or cardiovascular safety concerns. The results demonstrate excellent efficacy, tolerability and safety with darifenacin 7.5 mg and 15 mg once-daily treatment for OAB in older patients." @default.
• W2057928770 created "2016-06-24" @default.
• W2057928770 creator A5031133453 @default.
• W2057928770 creator A5076057519 @default.
• W2057928770 creator A5080285692 @default.
• W2057928770 creator A5089634946 @default.
• W2057928770 date "2005-09-01" @default.
• W2057928770 modified "2023-10-17" @default.
• W2057928770 title "Treatment of Overactive Bladder in the Older Patient: Pooled Analysis of Three Phase III Studies of Darifenacin, an M3 Selective Receptor Antagonist" @default.
• W2057928770 cites W1524480950 @default.
• W2057928770 cites W1967312126 @default.
• W2057928770 cites W1967340813 @default.
• W2057928770 cites W1974084711 @default.
• W2057928770 cites W1986115550 @default.
• W2057928770 cites W1989309123 @default.
• W2057928770 cites W1991693093 @default.
• W2057928770 cites W2006171475 @default.
• W2057928770 cites W2007829947 @default.
• W2057928770 cites W2038175753 @default.
• W2057928770 cites W2059185896 @default.
• W2057928770 cites W2080371558 @default.
• W2057928770 cites W2084419295 @default.
• W2057928770 cites W2088303839 @default.
• W2057928770 cites W2089864602 @default.
• W2057928770 cites W2131173377 @default.
• W2057928770 cites W2158087005 @default.
• W2057928770 cites W2161088063 @default.
• W2057928770 cites W2790209222 @default.
• W2057928770 cites W4293765665 @default.
• W2057928770 cites W2792296291 @default.
• W2057928770 doi "https://doi.org/10.1016/j.eururo.2005.05.009" @default.
• W2057928770 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15990219" @default.
• W2057928770 hasPublicationYear "2005" @default.
• W2057928770 type Work @default.
• W2057928770 sameAs 2057928770 @default.
• W2057928770 citedByCount "73" @default.
• W2057928770 countsByYear W20579287702012 @default.
• W2057928770 countsByYear W20579287702014 @default.
• W2057928770 countsByYear W20579287702015 @default.
• W2057928770 countsByYear W20579287702016 @default.
• W2057928770 countsByYear W20579287702017 @default.
• W2057928770 countsByYear W20579287702018 @default.
• W2057928770 countsByYear W20579287702020 @default.
• W2057928770 countsByYear W20579287702021 @default.
• W2057928770 countsByYear W20579287702022 @default.
• W2057928770 countsByYear W20579287702023 @default.
• W2057928770 crossrefType "journal-article" @default.
• W2057928770 hasAuthorship W2057928770A5031133453 @default.
• W2057928770 hasAuthorship W2057928770A5076057519 @default.
• W2057928770 hasAuthorship W2057928770A5080285692 @default.
• W2057928770 hasAuthorship W2057928770A5089634946 @default.
• W2057928770 hasConcept C126322002 @default.
• W2057928770 hasConcept C126894567 @default.
• W2057928770 hasConcept C142724271 @default.
• W2057928770 hasConcept C197934379 @default.
• W2057928770 hasConcept C204787440 @default.
• W2057928770 hasConcept C27081682 @default.
• W2057928770 hasConcept C2777912814 @default.
• W2057928770 hasConcept C2778375690 @default.
• W2057928770 hasConcept C2778941218 @default.
• W2057928770 hasConcept C2781112942 @default.
• W2057928770 hasConcept C71924100 @default.
• W2057928770 hasConcept C90924648 @default.
• W2057928770 hasConceptScore W2057928770C126322002 @default.
• W2057928770 hasConceptScore W2057928770C126894567 @default.
• W2057928770 hasConceptScore W2057928770C142724271 @default.
• W2057928770 hasConceptScore W2057928770C197934379 @default.
• W2057928770 hasConceptScore W2057928770C204787440 @default.
• W2057928770 hasConceptScore W2057928770C27081682 @default.
• W2057928770 hasConceptScore W2057928770C2777912814 @default.
• W2057928770 hasConceptScore W2057928770C2778375690 @default.
• W2057928770 hasConceptScore W2057928770C2778941218 @default.
• W2057928770 hasConceptScore W2057928770C2781112942 @default.
• W2057928770 hasConceptScore W2057928770C71924100 @default.
• W2057928770 hasConceptScore W2057928770C90924648 @default.
• W2057928770 hasIssue "3" @default.
• W2057928770 hasLocation W20579287701 @default.
• W2057928770 hasLocation W20579287702 @default.
• W2057928770 hasOpenAccess W2057928770 @default.
• W2057928770 hasPrimaryLocation W20579287701 @default.
• W2057928770 hasRelatedWork W1968865622 @default.
• W2057928770 hasRelatedWork W2003042623 @default.
• W2057928770 hasRelatedWork W2013908993 @default.
• W2057928770 hasRelatedWork W202460821 @default.
• W2057928770 hasRelatedWork W2029146777 @default.
• W2057928770 hasRelatedWork W2030348591 @default.
• W2057928770 hasRelatedWork W2071699168 @default.
• W2057928770 hasRelatedWork W2082897746 @default.
• W2057928770 hasRelatedWork W2109235243 @default.
• W2057928770 hasRelatedWork W2147941583 @default.
• W2057928770 hasVolume "48" @default.
• W2057928770 isParatext "false" @default.
• W2057928770 isRetracted "false" @default.
• W2057928770 magId "2057928770" @default.
• W2057928770 workType "article" @default.